SenesTech, Inc. (SNES) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. SenesTech, Inc. is a smaller reporting company developing and commercializing fertility control products for managing animal pest populations, primarily rats and mice. The company's product portfolio includes the legacy product ContraPest and the newer Evolve line (Evolve Rat and Evolve Mouse), which utilizes cottonseed oil as an active ingredient.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $625,000 | $1,110,000 | $459,000 | $874,000 |
| Gross Profit | $409,000 | $722,000 | $249,000 | $384,000 |
| Gross Margin | 65.4% | 65.0% | 54.2% | 43.9% |
| Net Loss | $(1,616,000) | $(3,281,000) | $(1,584,000) | $(3,416,000) |
| Cash & Equivalents (End of Period) | $6,055,000 (as of June 30, 2025) | |||
| Accumulated Deficit | $(139,378,000) | |||
| Operating Cash Flow (YTD) | $(2,707,000) | $(3,416,000) | ||
| Financing Cash Flow (YTD) | $7,538,000 | $14,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 36% in Q2 2025 compared to Q2 2024, driven primarily by the Evolve product line, which accounted for 83% of Q2 2025 revenue versus 58% in the prior year. Conversely, ContraPest sales declined.
- Margin Expansion: Gross margin improved significantly to 65.4% in Q2 2025 from 54.2% in Q2 2024. This was attributed to a favorable product mix shift toward Evolve (lower cost of sales) and the resolution of higher input costs seen in the prior year.
- Expense Management: Research and Development (R&D) expenses decreased 9% quarter-over-quarter due to personnel cost reductions, partially offset by increased facility costs from a new manufacturing site lease commencing in April 2025. Selling, General, and Administrative (SG&A) expenses increased 15%, largely due to higher legal fees related to ongoing litigation and increased franchise fees.
- Liquidity Position: Cash and cash equivalents increased from $1.3 million at year-end 2024 to $6.1 million at June 30, 2025. This improvement was driven by $7.5 million in net financing proceeds from warrant exercises and an At-The-Market (ATM) offering, offsetting a $2.7 million operating cash burn.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring significant operating losses in the near term. Based on current cash ($6.1 million) and anticipated revenue, the company believes it can fund operations through at least the end of fiscal 2027. However, additional financing may be required to achieve revenue and margin targets.
- Subsequent Events: On August 5, 2025, the company completed a warrant inducement transaction generating gross proceeds of $6.3 million, raising total cash to approximately $11.2 million.
- Going Concern: The company has an accumulated deficit of $139.4 million. While the recent capital raise extends the runway, the company notes that if it cannot generate sufficient revenue or raise additional capital, it may need to delay or discontinue operations.
- Legal Contingencies: The company is defending against a lawsuit filed by Liphatech Inc. alleging breach of contract and misappropriation of trade secrets. No damages have been accrued as the outcome is not probable or estimable.
Key Investor Verification Points
- Cash Runway: Verify the sufficiency of the $11.2 million cash balance (post-August 2025 transaction) against the projected burn rate to confirm the ability to operate through 2027 without further dilution.
- Product Mix Sustainability: Monitor the continued shift from ContraPest to Evolve to ensure gross margins remain elevated as ContraPest sales decline.
- Legal Exposure: Track the status of the Liphatech litigation for potential material adverse effects on financial position or operations.
- Financing Dependency: Assess the company's reliance on equity financing (warrant exercises and ATM offerings) to fund operations, noting the dilution impact on existing shareholders.